Munich - April 14, 2015
Press Release
GABO:mi collaborates in public-private partnership
validating blood-based biomarkers for cancer,
supported by Innovative Medicines Initiative (IMI)
April 14, 2015 – CANCER-ID is a public-private partnership with
currently 33 partners from 13 countries. Kicked off on January 1, 2015,
CANCER-ID comprises a European consortium that recently obtained
funding from Europe’s IMI Joint Undertaking. The consortium aims to
establish standard protocols for and clinical validation of blood-based
biomarkers. A total of 14.5 million euros was awarded to the
consortium, thereof 8.2 million euros funding by the industrial partners
and 6.3 million euros from the IMI.
Blood-based biomarkers such as circulating tumor cells (CTCs),
circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) are
potential indicators for the tumor burden of patients living with cancer.
Derivation of these markers from blood may offer an additional
invaluable tool for modern cancer therapy: apart from being of high
importance when biopsies of the tumor are not accessible, blood-based
tests may allow a close follow-up of disease markers offering a means to
monitor the efficacy of treatment and potentially improve the choice of
treatment options.
“Blood-based analysis of tumor derived cells and nucleic acids offer a
novel concept of liquid biopsies which allows to receive real-time
information relevant to cancer diagnosis and therapy. The CANCER-ID
project fills the substantial gap between basic research focused on novel
methods for the detection and characterization of circulating tumor cells
and nucleic acids and the development of robust validated assays
required to bring the liquid biopsy concept into the clinic”, says Prof.
Klaus Pantel, one of the academic project leads.
The Consortium
Leon Terstappen at University of Twente and Klaus Pantel at University
Medical Center Hamburg-Eppendorf are the academic leads of the
CANCER-ID consortium. GABO:mi, based in Munich, is in charge of the
project management. The EFPIA lead companies of the CANCER-ID
consortium are Bayer HealthCare and Silicon Biosystems, a Menarini
Group Company.
GABO:mi Gesellschaft für Ablauforganisation :milliarium mbH & Co. KG
Oskar-von-Miller-Ring 29 – 80333 Munich – Germany – phone +49-89-288104-0 – www.gabo-mi.com
Page 1 of 2
Munich - April 14, 2015
Press Release
About the Innovative Medicines Initiative (IMI)
The Innovative Medicines Initiative (IMI) is working to improve health by
speeding up the development of, and patient access to, innovative medicines,
particularly in areas where there is an unmet medical or social need. It does this
by facilitating collaboration between the key players involved in healthcare
research, including universities, the pharmaceutical and other industries, small
and medium-sized enterprises (SMEs), patient organizations and medicines
regulators.
CANCER-ID has received support from the IMI under grant agreement n°
[115749], resources of which are composed of financial contribution from the
European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA
companies’ in kind contribution.
About GABO:mi
GABO:mi is a project management company specialised in the management of
EU-funded research projects. Since it was founded in 2005, GABO:mi has
continually expanded its extensive expertise with diverse EU funding
instruments. GABO:mi has managed 40+ medium- and large-scale collaborative
projects funded by the European Commission to date.
Our project managers have vast and valuable experience in the management of
EU-funded projects. They are familiar with the underlying structures of
international collaborative research projects and their governing principles.
Additionally, they are always up-to-date with regard to the current regulations
of the European Commission and its agencies.
Project Logo
Press Contact
GABO:mi Gesellschaft für Ablauforganisation :milliarium mbH & Co. KG
Dr. Romana Lange-Ruiss
Phone: +49-89 288104-21
E-Mail: Romana.Lange-Ruiss@gabo-mi.com
www.gabo-mi.com
Social Media
Twitter
http://bit.ly/GABOmi_Twitter
GABO:mi Gesellschaft für Ablauforganisation :milliarium mbH & Co. KG
Oskar-von-Miller-Ring 29 – 80333 Munich – Germany – phone +49-89-288104-0 – www.gabo-mi.com
Page 2 of 2